Novartis variant 1 | Peptides | # of isolates (serogroup) |
---|---|---|
(Pfizer subfamily B) | 1.1 | 2 (B, two ST-32 cc) |
1.4 | 5 (B, four ST-41/44 cc, one ST-35 cc) | |
1.12 | 2 (B, one UAa; C, one ST-11 cc) | |
1.13 | 5 (B, one ST-60 cc, one ST-254 cc, two ST-1157 cc, one UA) | |
1.14 | 1 (B, ST-41/44 cc) | |
1.15 | 152 (B, 152 ST-269 cc) | |
1.100 | 1 (B, ST-41/44 cc) | |
1.110 | 1 (B, UA) | |
1.129 | 1 (C, ST-11 cc) | |
1.144 | 1 (B, ST-32 cc) | |
1.218 | 1 (C, ST-11 cc) | |
1.249 | 1 (B, ST-269 cc) | |
1.278 | 1 (Y, ST-167 cc) | |
1.410 | 4 (B, four ST-41/44 cc) | |
1.687 | 1 (B, ST-41/44 cc) | |
Novartis variant 2 | 2.16 | 15 (3B, three ST-35 cc; 1C, ST-11 cc; 2Y, one ST-22 cc; one UA; 9W, nine ST-22 cc) |
(Pfizer subfamily A) | ||
2.19 | 32 (31B, five ST-269 cc; 26 ST-41/44 cc; 1×, one ST-32 cc) | |
2.21 | 1 (Y, ST-174 cc) | |
2.22 | 1 (B, ST-32 cc) | |
2.23 | 6 (3B, two ST-41/44 CC; one ST-37 cc; 3Y, one ST-167 cc; two UA) | |
2.24 | 5 (4B, two ST-41/44 cc, two UA; 1Y, ST-167 cc) | |
2.25 | 9 (1B, ST-103 cc; 7Y, six ST-23 cc; one ST-167 cc; 1 W, ST-22 cc) | |
2.102 | 2 (1B, ST-213 cc; 1C, ST-11 cc) | |
2.106 | 1 (B, UA) | |
2.527 | 1 (B, UA) | |
2.629 | 1 (Y, UA) | |
2.632 | 1 (B, ST-41/44 cc) | |
Novartis variant 3 | 3.30 | 2 (B, ST-41/44 cc, ST-32 cc) |
(Pfizer subfamily A) | 3.47 | 2 (B, two ST-461 cc) |
3.555 | 1 (B, UA) | |
No peptide | allele 669 | 2 (C, two ST-11 cc) |
allele 755 | 1 (B, ST-269 cc) | |
Recombination | disrupted gene | 1 (B, UA) |